Results 71 to 80 of about 49,053 (243)
HIV Medicine, EarlyView.Abstract Objectives Aging people with HIV are increasingly affected by multimorbidity and polypharmacy, which heighten the risk of drug–drug interactions (DDIs) and potentially inappropriate medications (PIMs). This study evaluated a multidisciplinary, AI‐supported quality improvement intervention designed to optimize polypharmacy management in older ...
Jovana Milic +13 more
wiley +1 more source
, 2021 International audienceBackground: Little is known about the HIV-1 integrase resistance in CNS. This study aimed to evaluate integrase resistance in CSF, as a marker of CNS, and compare it to the HIV resistance in plasma.
Simon, Anne +13 more
core +1 more source
Clinical use of HIV integrase inhibitors: a systematic review and meta-analysis.
PLoS ONE, 2013 BackgroundOptimal regimen choice of antiretroviral therapy is essential to achieve long-term clinical success. Integrase inhibitors have swiftly been adopted as part of current antiretroviral regimens. The purpose of this study was to review the evidence
Peter Messiaen +5 more
doaj +1 more source
HIV Medicine, EarlyView.Abstract Background The potent immunogenicity of mRNA vaccination raised concerns about its impact on HIV‐1 viral load (VL) and reservoir size in people with HIV, which could drive vaccine hesitancy. As part of a prospective clinical trial, we investigated whether SARS‐CoV‐2 mRNA vaccination induced changes in VL and reservoir size after a 1‐year three‐
Oscar Kieri +8 more
wiley +1 more source
HIV Medicine, EarlyView.Abstract Background Data on changes in biomarkers of brain health, and their associations with cognitive function in adults commencing either dual‐ or triple‐antiretroviral therapy (ART) are sparse. Methods Plasma biomarkers (neurofilament light [NfL], glial fibrillary acidic protein [GFAP], sCD14, CXCL10, neopterin and IL‐6) were measured at baseline ...
Merle Henderson +13 more
wiley +1 more source
HIV Medicine, EarlyView.Abstract Background Age‐related comorbidities occur earlier and more frequently in people with HIV (PWH) than in the general population and have emerged as a key challenge in long‐term HIV care. Unfortunately, many of these conditions remain undiagnosed, and systematic screening in clinical practice remains limited.
Anna Katrine Haslund Roed +4 more
wiley +1 more source
Pharmacology of HIV integrase inhibitors [PDF]
Current Opinion in HIV and AIDS, 2012 The purpose of this paper is to review recent and relevant pharmacology data for three HIV integrase inhibitors: raltegravir (marketed), dolutegravir and elvitegravir (both in Phase III drug development).
Jessica L, Adams +2 more
openaire +2 more sources
HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa.
, 2011 Antiretroviral therapy for HIV-2 infection is hampered by intrinsic resistance to many of the drugs used to treat HIV-1. Limited studies suggest that the integrase inhibitors (INIs) raltegravir and elvitegravir have potent activity against HIV-2 in ...
Robert A Smith +28 more
core +1 more source
VirusesIntegrase strand transfer inhibitors (INSTI) are associated with neuropsychiatric adverse events (NPAEs). The aim of this study was to evaluate improvements in NPAEs after switching an INSTI-based regimen to darunavir/cobicistat (DRV/c) or doravirine ...
José Antonio Mata-Marín +8 more
doaj +1 more source
HIV Medicine, EarlyView.Abstract Introduction Two‐drug regimens (2DRs) may reduce long‐term drug toxicities and drug‐drug interactions for people with HIV (PWH) on antiretroviral therapy (ART). This study evaluated clinical and laboratory outcomes in PWH who switched from standard ART to dolutegravir and lamivudine (DTG + 3TC) in real‐world settings.
Tommy Hing‐cheung Tang +15 more
wiley +1 more source